(Reuters) -Several pharmaceutical companies have said they will sell drugs direct to patients in the U.S. and offered ...

Drugmakers feel empowered to resist foreign price controls — confident that the Trump administration will have their backs.

Two open-label extension studies show that the FcRn blocker nipocalimab has durable efficacy and sustained symptom control ...

Q3 2025 Earnings Call Transcript November 6, 2025 AstraZeneca PLC beats earnings expectations. Reported EPS is $1.19, ...

AstraZeneca is the biggest drugmaker in Britain and its £193 billion ($253 billion) market capitalization tops the London Stock Exchange.

President Donald Trump has unveiled a deal with drugmakers Eli Lilly and Novo Nordisk to expand coverage and reduce prices ...

Acknowledging China’s innovative biotech environment, UK-headquartered pharmaceutical company AstraZeneca said it is confident about further investing in the country, and working with local ...

AstraZeneca Pharma India reported a robust second quarter, with profit rising 41% year-on-year to ₹54.2 crore and revenue up 37%.

The condition, which most often affects people in warm, humid climates where fungal spores are common, can trigger nasal ...

Eli Lilly and Novo Nordisk have agreed pricing deals for GLP-1RA brands, a pivotal moment in the obesity treatment market.

Under the model, set to start next year, the CMS will negotiate lower prices for Medicaid programs linked to those paid in ...

Positive full results from the NATRON Phase III trial showed AstraZeneca’s FASENRA (benralizumab) demonstrated a statistically significant delay in the time to first worsening or flare in ...